Assessing the risk of Acute Kidney Injury (AKI)- A paradigm shift in renal care

Acute Kidney Injury (AKI) is one of the more prevalent and serious morbidities in hospitalized patients and is associated with a multitude of acute and chronic conditions. The economic and public health burden of AKI is significant with substantially increased mortality, morbidity, length of ICU stay and in-hospital costs. The NEPHROCHECK® Test [TIMP-2 • IGFBP-7] is an FDA cleared combination biomarker test that can significantly discriminate AKI from no-AKI, and when used in conjunction with clinical evaluation, can aid physicians in optimizing patient management.